

Lung Cancer Treatment **contro**versies



2026

06-07 NOVEMBER • PORTO



Preliminary Program

2026

06-07 NOVEMBER · PORTO



Organizing Committee / Scientific Coordinators

António Araújo

Unidade Local de Saúde Santo António /
School of Medicine and Biomedical Sciences –
ICBAS, University of Porto, Porto, Portugal

Delvys Rodriguez-Abreu

Hospital Universitario Insular, Las Palmas de
Gran Canaria, Spain

Luiz Paz-Ares

Hospital Universitario 12 de Octubre, Madrid, Spain

Stephen Liu

Lombardi Cancer Center Georgetown University,
Washington, USA

Position Paper Coordinator

Ana Rodrigues

Portuguese Institute of Oncology – Porto Center, Porto, Portugal

Scientific Panel

Alfredo Addeo ⁽¹⁾

Alvaro Quintanal-Villalonga ⁽²⁾

Andrea Ardizzoni ⁽³⁾

António Araújo ⁽⁴⁾

Benjamin Besse ⁽⁵⁾

Cecilia Pompili ⁽⁶⁾

Christian Rolfo ⁽⁷⁾

Delvys Rodriguez-Abreu ⁽⁸⁾

Enriqueta Felip ⁽⁹⁾

Fiona Blackhall ⁽¹⁰⁾

Joachim Aerts ⁽¹¹⁾

Jessica Lin ⁽¹²⁾

Jordi Remon ⁽¹³⁾

Lizza Hendriks ⁽¹⁴⁾

Luiz Paz-Ares ⁽¹⁵⁾

Martin Reck ⁽¹⁶⁾

Rosario Garcia Campelo ⁽¹⁷⁾

Stephen Liu ⁽¹⁸⁾

Suresh Senan ⁽¹⁹⁾



General Information

Venue:

School of Medicine and
Biomedical Sciences – ICBAS,
University of Porto
Rua de Jorge de Viterbo Ferreira, 228,
4050-313 Porto

Technical Secretary:

Skyros Congressos, Lda

Format:

Short lectures, pro-con
debates, to draw conclusions
from the debate and to vote
among all the audience.

Language:

English

Audience:

Thoracic oncologists,
surgeons, radiation
oncologists, translational
researchers.



Day 1 – Morning

Friday, 6 November

08:15 › Registration opening

08:45–09:00 › Welcome & Objectives

09:00–13:00 › Session 1

Early Stages: Are We Over or Under-Treating?

Chairs: *Delvys Rodriguez-Abreu & Christian Rolfo*

Controversies – Pro and Con (10' each talk followed 40' for discussion and conclusions)

■ Perioperative vs neo-adjuvant IO.

Speakers: *Lizza Hendriks vs Alfredo Addeo*

■ Are we ready for targeted therapy in resected oncogene-driven NSCLC?

Speakers: *Jessica Lin vs Rosario Garcia Campelo*

10:45–11:15 › Coffee Break

■ Should MRD guide adjuvant therapy in 2026?

Speaker: *Christian Rolfo*

■ In multiple station N2, bulky N2 or T4 – Neoadjuvant pre-surgery or chemoradiation and IO?

Speakers: *Cecilia Pompili vs Suresh Senan*

13:00–14:00 › Lunch



Day 1 – Afternoon

Friday, 6 November

14:00–18:00 › Session 2

First-line Treatment for advanced NSCLC: what is the size?

Chairs: *Stephen Liu & Jessica Lin*

Controversies – *Pro and Con (10' each talk followed 40' for discussion and conclusions)*

■ In PD-L1 $\geq$ 50% IO alone vs chemo-IO or IO combinations.

Speakers: *Stephen Liu vs Enriqueta Felip*

■ Sequencing vs combinations in oncogene-driven disease.

Speakers: *Delvys Rodriguez-Abreu vs Jessica Lin*

15:45–16:15 › Coffee Break

■ What is the best duration of the IO therapy? Two years vs until disease progression.

Speakers: *Benjamin Besse vs Joachim Aerts*

■ The value of new strategies (like ADCs or bispecific antibodies) vs (and) the need for new biomarkers.

Speaker: *Jordi Remon*

19:30 › Networking Dinner



Day 2 – Morning

Saturday, 7 November

09:00–13:00 › Session 3

mSCLC: is this the future?

Chairs: *António Araújo & Luiz Paz-Ares*

Controversies – Pro and Con (10' each talk followed 40' for discussion and conclusions)

■ Molecular subtypes and other biomarkers: ready for clinical use?

Speaker: *Alvaro Quintanal-Villalonga*

■ Maintenance with PD-L1/PD-1 inhibitors or Lurbinectedin+Atezolizumab?

Speakers: *Andrea Ardizzoni vs Martin Reck*

10:45–11:15 › Coffee Break

■ T-Cells Engager – some patients in some centers or most patients in most centers?

Speakers: *Fiona Blackhall vs Luiz Paz-Ares*

■ After chemo-immunotherapy progression: should we move directly to T-cell engagers or still sequence conventional therapies?

Speakers: *Benjamin Besse vs Stephen Liu*

13:00–13:30 › Closing Session

■ Take-home messages and consensus gaps

■ Proposal for post-meeting position paper